Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Response to letter regarding article 'Fingolimod effects on left ventricular function in multiple sclerosis'.
Adolescent-onset Krabbe disease with an initial diagnosis of multiple sclerosis and a novel mutation.
Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls.
Thalamic Atrophy is Associated with Development of Clinically Definite Multiple Sclerosis.
G protein-coupled receptors as therapeutic targets for multiple sclerosis.
Serum antibodies to 25 myelin oligodendrocyte glycoprotein epitopes in multiple sclerosis and neuromyelitis optica: clinical value for diagnosis and disease activity.
Astrogliosis During Acute and Chronic Cuprizone Demyelination and Implications for Remyelination.
Cerebrospinal Fluid IL-21 Levels in Neuromyelitis Optica and Multiple Sclerosis.
Slowing of information processing speed without motor slowing in multiple sclerosis observed during two crossing-off tasks.
Modulating effects of WT1 on interferon-β-vitamin D association in MS.
School performance as a marker of cognitive decline prior to diagnosis of multiple sclerosis.
Natalizumab as a Disease-Modifying Therapy in Chronic Inflammatory Demyelinating Polyneuropathy - A Report of Three Cases.
Laparoscopic implantation of neuromodulators for treating urinary dysfunctions and improving locomotion in multiple sclerosis patients.
Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity.
Extracellular Vesicles in Multiple Sclerosis: What are They Telling Us?
The role of complement in inflammatory diseases from behind the scenes into the spotlight.
Factors associated with clinically significant increased walking time in multiple sclerosis: Results of a survival analysis of short-term follow-up data from a clinical database.
[Acute disseminated encephalomyelitis (ADEM): its diagnostic criteria and therapy].
Polyomavirus JC infection inhibits differentiation of oligodendrocyte progenitor cells.
Cell-Based Reporter Gene Assay for Therapy-Induced Neutralizing Antibodies to Interferon-Beta in Multiple Sclerosis.
M. paratuberculosis Heat Shock Protein 65 and Human Diseases: Bridging Infection and Autoimmunity.
Initial investigation of the blood-brain barrier in MS lesions at 7 tesla.
Ascl1/Mash1 Promotes Brain Oligodendrogenesis during Myelination and Remyelination.
A new model of cuprizone-mediated demyelination/remyelination.
HLA-DRB1*15 influences the development of brain tissue damage in early PPMS.
Pages
« first
‹ previous
…
354
355
356
357
358
359
360
361
362
…
next ›
last »